Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · IEX Real-Time Price · USD
3.310
+0.190 (6.09%)
Jul 19, 2024, 4:00 PM EDT - Market closed

Company Description

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases.

It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease.

The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Dr. Regina Graul Ph.D.

Contact Details

Address:
301 Binney Street
Cambridge, Massachusetts 02142
United States
Phone 617-621-7722
Website cyclerion.com

Stock Details

Ticker Symbol CYCN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001755237
CUSIP Number 23255M105
ISIN Number US23255M2044
Employer ID 83-1895370
SIC Code 2834

Key Executives

Name Position
Dr. Regina Graul Ph.D. President
Rhonda M. Chicko Chief Financial Officer
Dr. Todd Milne Ph.D. Senior Vice President of External Innovation
Jessica Rennekamp Associate Director of Corporate Communications

Latest SEC Filings

Date Type Title
Jul 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jun 14, 2024 8-K Current Report
May 7, 2024 10-Q Quarterly Report
Apr 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2024 DEF 14A Other definitive proxy statements
Apr 18, 2024 8-K Current Report
Mar 5, 2024 10-K Annual Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals